Efficacy and safety of dasatinib in imatinib-resistant or -intolerant patients with chronic myeloid leukemia in blast phase
10.1038/leu.2008.221
Crossref journal-article
Springer Science and Business Media LLC
Leukemia (297)
Bibliography

Cortes, J., Kim, D.-W., Raffoux, E., Martinelli, G., Ritchie, E., Roy, L., Coutre, S., Corm, S., Hamerschlak, N., Tang, J.-L., Hochhaus, A., Khoury, H. J., Brümmendorf, T. H., Michallet, M., Rege-Cambrin, G., Gambacorti-Passerini, C., Radich, J. P., Ernst, T., Zhu, C., … Talpaz, M. (2008). Efficacy and safety of dasatinib in imatinib-resistant or -intolerant patients with chronic myeloid leukemia in blast phase. Leukemia, 22(12), 2176–2183.

Authors 21
  1. J Cortes (first)
  2. D-W Kim (additional)
  3. E Raffoux (additional)
  4. G Martinelli (additional)
  5. E Ritchie (additional)
  6. L Roy (additional)
  7. S Coutre (additional)
  8. S Corm (additional)
  9. N Hamerschlak (additional)
  10. J-L Tang (additional)
  11. A Hochhaus (additional)
  12. H J Khoury (additional)
  13. T H Brümmendorf (additional)
  14. M Michallet (additional)
  15. G Rege-Cambrin (additional)
  16. C Gambacorti-Passerini (additional)
  17. J P Radich (additional)
  18. T Ernst (additional)
  19. C Zhu (additional)
  20. J M A Van Tornout (additional)
  21. M Talpaz (additional)
References 30 Referenced 149
  1. Derderian PM, Kantarjian HM, Talpaz M, O’Brien S, Cork A, Estey E et al. Chronic myelogenous leukemia in the lymphoid blastic phase: characteristics, treatment response, and prognosis. Am J Med 1993; 94: 69–74. (10.1016/0002-9343(93)90122-6) / Am J Med by PM Derderian (1993)
  2. Hochhaus A, La Rosée P . Imatinib therapy in chronic myelogenous leukemia: strategies to avoid and overcome resistance. Leukemia 2004; 18: 1321–1331. (10.1038/sj.leu.2403426) / Leukemia by A Hochhaus (2004)
  3. Sacchi S, Kantarjian HM, O’Brien S, Cortes J, Rios MB, Giles FJ et al. Chronic myelogenous leukemia in nonlymphoid blastic phase: analysis of the results of first salvage therapy with three different treatment approaches for 162 patients. Cancer 1999; 86: 2632–2641. (10.1002/(SICI)1097-0142(19991215)86:12<2632::AID-CNCR7>3.0.CO;2-A) / Cancer by S Sacchi (1999)
  4. Wadhwa J, Szydlo RM, Apperley JF, Chase A, Bua M, Marin D et al. Factors affecting duration of survival after onset of blastic transformation of chronic myeloid leukemia. Blood 2002; 99: 2304–2309. (10.1182/blood.V99.7.2304) / Blood by J Wadhwa (2002)
  5. Sawyers CL, Hochhaus A, Feldman E, Goldman JM, Miller CB, Ottmann OG et al. Imatinib induces hematologic and cytogenetic responses in patients with chronic myelogenous leukemia in myeloid blast crisis: results of a phase II study. Blood 2002; 99: 3530–3539. (10.1182/blood.V99.10.3530) / Blood by CL Sawyers (2002)
  6. Ottmann OG, Druker BJ, Sawyers CL, Goldman JM, Reiffers J, Silver RT et al. A phase 2 study of imatinib in patients with relapsed or refractory Philadelphia chromosome-positive acute lymphoid leukemias. Blood 2002; 100: 1965–1971. (10.1182/blood-2001-12-0181) / Blood by OG Ottmann (2002)
  7. Soverini S, Martinelli G, Rosti G, Bassi S, Amabile M, Poerio A et al. ABL mutations in late chronic phase chronic myeloid leukemia patients with up-front cytogenetic resistance to imatinib are associated with a greater likelihood of progression to blast crisis and shorter survival: a study by the GIMEMA Working Party on Chronic Myeloid Leukemia. J Clin Oncol 2005; 23: 4100–4109. (10.1200/JCO.2005.05.531) / J Clin Oncol by S Soverini (2005)
  8. Lombardo LJ, Lee FY, Chen P, Norris D, Barrish JC, Behnia K et al. Discovery of N-(2-chloro-6-methyl-phenyl)-2-(6-(4-(2-hydroxyethyl)-piperazin-1-yl)-2-methylpyrimidin-4-ylamino)thiazole-5-carboxamide (BMS-354825), a dual Src/Abl kinase inhibitor with potent antitumor activity in preclinical assays. J Med Chem 2004; 47: 6658–6661. (10.1021/jm049486a) / J Med Chem by LJ Lombardo (2004)
  9. Talpaz M, Shah NP, Kantarjian H, Donato N, Nicoll J, Paquette R et al. Dasatinib in imatinib-resistant Philadelphia chromosome-positive leukemias. N Engl J Med 2006; 354: 2531–2541. (10.1056/NEJMoa055229) / N Engl J Med by M Talpaz (2006)
  10. Cortes J, Rousselot P, Kim DW, Ritchie E, Hamerschlak N, Coutre S et al. Dasatinib induces complete hematologic and cytogenetic responses in patients with imatinib-resistant or -intolerant chronic myeloid leukemia in blast crisis. Blood 2007; 109: 3207–3213. (10.1182/blood-2006-09-046888) / Blood by J Cortes (2007)
  11. Clopper C, Pearson E . The use of confidence or fiducial limits illustrated in the case of the binomial. Biometrika 1934; 26: 404–413. (10.1093/biomet/26.4.404) / Biometrika by C Clopper (1934)
  12. Hochhaus A, Baccarani M, Deininger M, Apperley JF, Lipton JH, Goldberg SL et al. Dasatinib induces durable cytogenetic responses in patients with chronic myelogenous leukemia in chronic phase with resistance or intolerance to imatinib. Leukemia 2008; 22: 1200–1206. (10.1038/leu.2008.84) / Leukemia by A Hochhaus (2008)
  13. Guilhot F, Apperley J, Kim DW, Bullorsky EO, Baccarani M, Roboz GJ et al. Dasatinib induces significant hematologic and cytogenetic responses in patients with imatinin-resistant or -intolerant chronic myeloid leukemia. Blood 2007; 109: 4143–4150. (10.1182/blood-2006-09-046839) / Blood by F Guilhot (2007)
  14. O’Hare T, Walters DK, Stoffregen EP, Jia T, Manley PW, Mestan J et al. In vitro activity of Bcr-Abl inhibitors AMN107 and BMS-354825 against clinically relevant imatinib-resistant Abl kinase domain mutants. Cancer Res 2005; 65: 4500–4505. (10.1158/0008-5472.CAN-05-0259) / Cancer Res by T O’Hare (2005)
  15. Shah NP, Tran C, Lee FY, Chen P, Norris D, Sawyers CL et al. Overriding imatinib resistance with a novel ABL kinase inhibitor. Science 2004; 305: 399–401. (10.1126/science.1099480) / Science by NP Shah (2004)
  16. Radich JP . The biology of CML blast crisis. Hematology (Am Soc Hematol Educ Program) 2007; 2007: 384–391. (10.1182/asheducation-2007.1.384) / Hematology (Am Soc Hematol Educ Program) by JP Radich (2007)
  17. Wilson MB, Schreiner SJ, Choi HJ, Kamens J, Smithgall TE . Selective pyrrolo-pyrimidine inhibitors reveal a necessary role for Src family kinases in Bcr-Abl signal transduction and oncogenesis. Oncogene 2002; 21: 8075–8088. (10.1038/sj.onc.1206008) / Oncogene by MB Wilson (2002)
  18. Klejman A, Schreiner SJ, Nieborowska-Skorska M, Slupianek A, Wilson M, Smithgall TE et al. The Src family kinase Hck couples BCR/ABL to STAT5 activation in myeloid leukemia cells. EMBO J 2002; 21: 5766–5774. (10.1093/emboj/cdf562) / EMBO J by A Klejman (2002)
  19. Lionberger JM, Wilson MB, Smithgall TE . Transformation of myeloid leukemia cells to cytokine independence by Bcr-Abl is suppressed by kinase-defective Hck. J Biol Chem 2000; 275: 18581–18585. (10.1074/jbc.C000126200) / J Biol Chem by JM Lionberger (2000)
  20. Meyn III MA, Wilson MB, Abdi FA, Fahey N, Schiavone AP, Wu J et al. Src family kinases phosphorylate the Bcr-Abl SH3-SH2 region and modulate Bcr-Abl transforming activity. J Biol Chem 2006; 281: 30907–30916. (10.1074/jbc.M605902200) / J Biol Chem by MA Meyn III (2006)
  21. Hu Y, Swerdlow S, Duffy TM, Weinmann R, Lee FY, Li S . Targeting multiple kinase pathways in leukemic progenitors and stem cells is essential for improved treatment of Ph+ leukemia in mice. Proc Natl Acad Sci USA 2006; 103: 16870–16875. (10.1073/pnas.0606509103) / Proc Natl Acad Sci USA by Y Hu (2006)
  22. Donato NJ, Wu JY, Stapley J, Gallick G, Lin H, Arlinghaus R et al. BCR-ABL independence and LYN kinase overexpression in chronic myelogenous leukemia cells selected for resistance to STI571. Blood 2003; 101: 690–698. (10.1182/blood.V101.2.690) / Blood by NJ Donato (2003)
  23. Ptasznik A, Nakata Y, Kalota A, Emerson SG, Gewirtz AM . Short interfering RNA (siRNA) targeting the Lyn kinase induces apoptosis in primary, and drug-resistant, BCR-ABL1(+) leukemia cells. Nat Med 2004; 10: 1187–1189. (10.1038/nm1127) / Nat Med by A Ptasznik (2004)
  24. Dai Y, Rahmani M, Corey SJ, Dent P, Grant S . A Bcr/Abl-independent, Lyn-dependent form of imatinib mesylate (STI-571) resistance is associated with altered expression of Bcl-2. J Biol Chem 2004; 279: 34227–34239. (10.1074/jbc.M402290200) / J Biol Chem by Y Dai (2004)
  25. Ito T, Tanaka H, Kimura A . Establishment and characterization of a novel imatinib-sensitive chronic myeloid leukemia cell line MYL, and an imatinib-resistant subline MYL-R showing overexpression of Lyn. Eur J Haematol 2007; 78: 417–431. (10.1111/j.1600-0609.2007.00835.x) / Eur J Haematol by T Ito (2007)
  26. Quintás-Cardama A, Kantarjian H, O’Brien S, Borthakur G, Bruzzi J, Munden R et al. Pleural effusion in patients with chronic myelogenous leukemia treated with dasatinib after imatinib failure. J Clin Oncol 2007; 25: 3908–3914. (10.1200/JCO.2007.12.0329) / J Clin Oncol by A Quintás-Cardama (2007)
  27. Heuchel R, Berg A, Tallquist M, Ahlen K, Reed RK, Rubin K et al. Platelet-derived growth factor beta receptor regulates interstitial fluid homeostasis through phosphatidylinositol-3′ kinase signaling. Proc Natl Acad Sci USA 1999; 96: 11410–11415. (10.1073/pnas.96.20.11410) / Proc Natl Acad Sci USA by R Heuchel (1999)
  28. de Lavallade H, Punnialingam S, Milojkovic D, Bua M, Khorashad JS, Gabriel IH et al. Pleural effusions in patients with chronic myeloid leukaemia treated with dasatinib may have an immune-mediated pathogenesis. Br J Haematol 2008; 141: 745–747. (10.1111/j.1365-2141.2008.07108.x) / Br J Haematol by H de Lavallade (2008)
  29. Sneed TB, Kantarjian HM, Talpaz M, O’Brien S, Rios MB, Bekele BN et al. The significance of myelosuppression during therapy with imatinib mesylate in patients with chronic myelogenous leukemia in chronic phase. Cancer 2004; 100: 116–121. (10.1002/cncr.11863) / Cancer by TB Sneed (2004)
  30. Druker BJ, Guilhot F, O’Brien SG, Gathmann I, Kantarjian H, Gattermann N et al. Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia. N Engl J Med 2006; 355: 2408–2417. (10.1056/NEJMoa062867) / N Engl J Med by BJ Druker (2006)
Dates
Type When
Created 17 years ago (Aug. 28, 2008, 5:48 a.m.)
Deposited 3 years, 5 months ago (March 31, 2022, 7:15 a.m.)
Indexed 1 week, 1 day ago (Aug. 28, 2025, 8:25 a.m.)
Issued 17 years ago (Aug. 28, 2008)
Published 17 years ago (Aug. 28, 2008)
Published Online 17 years ago (Aug. 28, 2008)
Published Print 16 years, 9 months ago (Dec. 1, 2008)
Funders 0

None

@article{Cortes_2008, title={Efficacy and safety of dasatinib in imatinib-resistant or -intolerant patients with chronic myeloid leukemia in blast phase}, volume={22}, ISSN={1476-5551}, url={http://dx.doi.org/10.1038/leu.2008.221}, DOI={10.1038/leu.2008.221}, number={12}, journal={Leukemia}, publisher={Springer Science and Business Media LLC}, author={Cortes, J and Kim, D-W and Raffoux, E and Martinelli, G and Ritchie, E and Roy, L and Coutre, S and Corm, S and Hamerschlak, N and Tang, J-L and Hochhaus, A and Khoury, H J and Brümmendorf, T H and Michallet, M and Rege-Cambrin, G and Gambacorti-Passerini, C and Radich, J P and Ernst, T and Zhu, C and Van Tornout, J M A and Talpaz, M}, year={2008}, month=aug, pages={2176–2183} }